Feds making ‘assessment of demand’ from provinces for Johnson & Johnson vaccine supply – National

Procurement Minister Anita Anand says the federal authorities is conducting an “assessment of demand” for Johnson & Johnson’s COVID-19 vaccine supply with provinces and territories.

“Decisions are still being made regarding the J&J vaccine deliveries, but by all means, that contract is still in place and still able to yield vaccines for Canadians if the demand is there,” Anand stated Tuesday.

The single-dose vaccine was initially lauded as a turning level for international locations corresponding to Canada trying to velocity up vaccination efforts.

Read extra:
Canada to maintain holding again J&J COVID-19 vaccines till U.S. lab probe is full

But after a producing mishap at a U.S. manufacturing plant in Baltimore, Health Canada stated it wouldn’t launch greater than 300,000 doses of the vaccine over high quality issues and can proceed to carry them again till an American investigation into the ability is full.

Story continues beneath commercial

Canada has signed an settlement for 10 million doses of the J&J shot. Joelle Paquette, the director-normal accountable for vaccine procurement at Public Services and Procurement Canada, stated Friday that the nation may anticipate to obtain a cargo of the vaccines by the tip of June, however whether or not any shipments have been delivered stays unclear.

Global News reached out to Anand’s workplace to verify vaccine shipments however didn’t instantly hear again.


Click to play video: 'Johnson & Johnson COVID-19 vaccine recommended for adults 30+ in Canada: NACI'







Johnson & Johnson COVID-19 vaccine advisable for adults 30+ in Canada: NACI


Johnson & Johnson COVID-19 vaccine advisable for adults 30+ in Canada: NACI – May 3, 2021

Brig. Gen. Krista Brodie, the army commander in cost of the nation’s nationwide vaccine supply logistics, stated that “at this point in time, we are not receiving a strong demand signal at all from the provinces” for J&J photographs.

“We are focused on the mRNA vaccines, which are those that are really in demand by the provinces in order to accelerate those second dose strategies and to really get as many first doses as we can as soon as possible.”

Story continues beneath commercial

J&J’s one-shot vaccine differs from Pfizer-BioNtech and Moderna’s mRNA vaccines, which require two doses. It is an adenovirus-primarily based vaccine that confirmed an total efficacy of 66 per cent in stopping reasonable to extreme COVID-19 in medical trials.

It was advisable for adults aged 30 years and older in May.

By the tip of this week, Canada is anticipated to have obtained deliveries of 50 million doses of all vaccines for use by Health Canada — the overwhelming majority of which being photographs from Pfizer and Moderna.

More to return. 

–With recordsdata from Global News’ Saba Aziz and the Canadian Press

View hyperlink »





© 2021 Global News, a division of Corus Entertainment Inc.


Latest Travel News